Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis

References

• World Health Organization. Global Tuberculosis Report 2017. 2017, World Health Organization: Geneva, Switzerland.
   Google Scholar
• World Health Organization. Multidrug-Resistant Tuberculosis (MDR-TB) 2017 Fact Sheet Update. 2017.
   Google Scholar
• World Health Organization. TB drug resistance types. [cited 2018 June].  Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/types/en/.
   Google Scholar
• World Health Organization. The End TB Strategy. 2015: Geneva, Switzerland.
   Google Scholar
• World Health Organization. Guidelines for treatment of drug-resistant tuberculosis. 2016: Geneva, Switzerland.
   Google Scholar
• World Health Organization. The shorter MDR-TB regimen FactSheet. (May 2016).
   Google Scholar
• Reuter A, Tisile P, Von Delft D, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis. 2017;21(11):1114–1126. .
   PubMed Web of Science ®Google Scholar
• Arnold A, Cooke GS, Kon OM, et al. Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(9).
   Web of Science ®Google Scholar
• Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–524.
   PubMed Web of Science ®Google Scholar
• Sagwa EL, Ruswa N, Mavhunga F, et al. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol. 2015;16:36.
   PubMed Web of Science ®Google Scholar
• Melchionda V, Wyatt H, Capocci S, et al. Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Eur Respir J. 2013;42(4):1148–1150.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40(5):1277–1286.
   PubMed Web of Science ®Google Scholar
• Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5.
   PubMedGoogle Scholar
• Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013;3(1):1–2.
   PubMedGoogle Scholar
• Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015;8:367–378.
   PubMed Web of Science ®Google Scholar
• FDA. Janssen Products. SIRTURO (bedaquiline) Prescribing Information 2018.
   Google Scholar
• DR-TB Scale-Up Treatment Action team (DR-TB STAT). Global Snapshot. [Cited 2018 Jun 28, 2018]; Available from: http://drtb-stat.org/global-snapshot/.
   Google Scholar
• Schnippel K, Firnhaber C, Conradie F, et al. Incremental cost effectiveness of bedaquiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis. Appl Health Econ Health Policy. 2018;16(1):43–54. .
   PubMed Web of Science ®Google Scholar
• Lu X, Smare C, Kambili C, et al. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Serv Res. 2017;17(1):87. .
   PubMedGoogle Scholar
• Van Deun A, Decroo T, Piubello A, et al. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis. 2018;22(3):239–245.
   PubMed Web of Science ®Google Scholar
• Mehra M, Kambili C, Potluri R, et al. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India. Int J Tuberc Lung Dis. 2017;21(8):902–909.
   PubMed Web of Science ®Google Scholar
• Vassall AW. Cost effectiveness of introducing bedaquiline in MDR-TB regimens an exploratory analysis. 2013.
   Google Scholar
• Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5):1800544.
   PubMed Web of Science ®Google Scholar
• Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.
   PubMed Web of Science ®Google Scholar
• Skrahina A. Bedaquiline in MDR-TB treatment: Belarus experience. IJM. 2016;5:S62–S63.
   Google Scholar
• Pym A, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of MDR and XDR-TB. ERJ. 2016;47(2):564–574.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. MDR-TB and culture conversion with bedaquiline. NEJM. 2014;371:723–732.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multidrug resistant tuberculosis. 2013.
   Google Scholar
• World Health Organization. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis: A review of available evidence (2016) 2017.
   Google Scholar
• Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med, 2018.
   Google Scholar
• Government of South Africa. Health releases data on reduction in TB mortality cases. 2018; [cited 2018 June]. Available from: https://www.gov.za/speeches/health-releases-data-reduction-tb-mortality-case-19-jun-2018-0000.
   Google Scholar
• Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–821.
   PubMed Web of Science ®Google Scholar
• The Russian Society of Phthisiatricians. Federal Clinical Recommendations for diagnosis and treatment tuberculosis of the respiratory system with multiple and broad medicinal resistance of the pathogen. 2015.
   Google Scholar
• The Stop TB Partnership. GDF products list. 2016 Jun 13, 2018]; Available from: http://www.stoptb.org/gdf/drugsupply/drugs_available.asp.
   Google Scholar
• India National Pharmaceutical Pricing Authority. Price fixing order. 2018 Jun 13, 2018]; Available from: http://www.nppaindia.nic.in/ceiling/press02April18/Formulation_Prices(841).pdf.
   Google Scholar
• Sharma A, Hill A, Kurbatova E, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis. 2017;17(7):707–715.
   PubMed Web of Science ®Google Scholar
• Russia State Authority. National Register of selling prices. 2018. [cited 2018 June]. Available from: www.grls.rosminzdrav.ru.
   Google Scholar
• Russian Government. Unified information system in the sphere of procurement. [cited 2018 June]. Available from www.zakupki.gov.ru.
   Google Scholar
• Pooran A, Pieterson E, Davids M, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587.
   PubMed Web of Science ®Google Scholar
• Schnippel K, Firnhaber C, Berhanu R, et al. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018;22(4):393–398.
   PubMed Web of Science ®Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308.
   Web of Science ®Google Scholar
• Government of India, M.o.H.F.W. Central Tuberculosis Division, Guideline for PMDT in India. 2017.
   Google Scholar
• Government of South Africa, Introduction of new drugs and drug regimens for the management of drug resistant tuberculosis in South Africa: policy framework. 2015.
   Google Scholar
• World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. Morbidity and Mortality Weekly Report. 2006;55:1176.
   Google Scholar
• Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) (indicator). 2018. [Cited 2018 Jun 11]; Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.
   Google Scholar
• Laserson KF, Kenyon AS, Kenyon TA, et al. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis. 2001;5(5):448–454.
   PubMed Web of Science ®Google Scholar
• Bate R, Jensen P, Hess K, et al. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis. 2013;17(3):308–311.
   PubMed Web of Science ®Google Scholar
• The StopTB Partnership 14 June 2018, USD 31 Million Saved by Stop TB Partnership’s Global Drug Facility Through Newly-Reduced Prices for TB Medicines. 2018.
   Google Scholar
• World Health Organization (WHO). Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• World Health Organization, Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: Data analysis report. 2016.
   Google Scholar
• Government of India. National Strategic Plan for tuberculosis elimination 2017–2025. 2017; [cited 2018 June]. Available from: https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf.
   Google Scholar
• Floyd K, Hutubessy R, Samyshkin Y, et al. Health-systems efficiency in the Russian Federation: tuberculosis control. Bull World Health Organ. 2006;84(1):43–51.
   PubMed Web of Science ®Google Scholar
• Satyanarayana S, Subbaraman R, Shete P, et al. Quality of tuberculosis care in India: a systematic review. Int J Tuberc Lung Dis. 2015;19(7):751–763.
   PubMed Web of Science ®Google Scholar
• Zinatsa F, Osborne EL, Assefa MT, et al. Voices from the frontline: barriers and strategies to improve tuberculosis infection control in primary health care facilities in South Africa. BMC Health Serv Res. 2018;18(1):269.
   PubMedGoogle Scholar
• Loveday M, Wallengren K, Brust J, et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;19(2):163–171.
   PubMed Web of Science ®Google Scholar
• John D, Chatterjee P, Murthy S, et al. Cost effectiveness of decentralised care model for managing MDR-TB in India. Indian Journal of Tuberculosis; 2017;65(3):208–217.
   Google Scholar
• Schnippel K, Firnhaber C, Page-Shipp L, et al. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018;22(8):918–925.
   PubMed Web of Science ®Google Scholar
• Kodama C, Wedzicha JA, Iversen M, et al. Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis. Eur Respir J. 2017;50(4):1701044.
   PubMed Web of Science ®Google Scholar
• Mandal S, Arinaminpathy N. Transmission modeling and health systems: the case of TB in India. Int Health. 2015;7(2):114–120.
   PubMed Web of Science ®Google Scholar
• Kunkel A, Cobelens FG, Cohen T, et al. Tradeoffs in introduction policies for the anti-tuberculosis drug bedaquiline: a model-based analysis. PLoS Med. 2016;13(10):e1002142.
   PubMed Web of Science ®Google Scholar
• Ahuja SD, Ashkin D, Avendano M, et al. Correction: multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(9).
   PubMedGoogle Scholar